tirzepatide court ruling Lilly Suffers Legal Loss in Case Against Compounding Pharmacy A Judge Just Shut Down

Tirzepatide in 2026 While semaglutide targets the GLP-1 receptor exclusively, tirzepatide activates both GLP-1 and GIP receptorsa dual-agonist mechanism showing slightly higher average weight loss (21-23%) in head-to-head comparisons

shifts in TSH during early GLP-1 treatment may reflect weight-related metabolic adjustment rather than medication harm, but tracking trends ensures safety

The 0.25 mg dose is sub-therapeutic for weight loss in many people

The conclusion was that, as long as stable mixed hemopoietic chimerism after BMT can be achieved, patients can be cured of their SCD without complete replacement of their bone marrow (Walters et al., 2001)